Get the Stockscreener App
46.25
1.34%
0.61
Pre-market:
46.27
0.02
+0.04%
Guardant Health Inc stock is traded at $46.25, with a volume of 2.08M.
It is up +1.34% in the last 24 hours and down -5.88% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$45.64
Open:
$45.31
24h Volume:
2.08M
Relative Volume:
0.96
Market Cap:
$5.73B
Revenue:
$692.26M
Net Income/Loss:
$-512.41M
P/E Ratio:
-10.91
EPS:
-4.24
Net Cash Flow:
$-274.36M
1W Performance:
-3.83%
1M Performance:
-5.88%
6M Performance:
-2.01%
1Y Performance:
+44.53%
1-Day Range:
$45.07
$46.43
1-Week Range:
$45.07
$49.30
52-Week Range:
$20.14
$53.42
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
46.25 | 5.96B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
427.62 | 157.79B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.91 | 138.02B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
532.00 | 42.36B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
116.19 | 32.08B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
187.38 | 27.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
3 Reasons to Avoid GH and 1 Stock to Buy Instead - FinancialContent
Guardant Health Inc. Stock Analysis and ForecastFree Capital Allocation Plans - jammulinksnews.com
Is Guardant Health Inc. a good long term investmentFree Consultation - jammulinksnews.com
Cathie Wood’s ARK ETFs shift focus, buying NVIDIA and selling GUARDANT - Investing.com
What analysts say about Guardant Health Inc. stockConsistently superior profits - jammulinksnews.com
What drives Guardant Health Inc. stock priceExplosive wealth accumulation - jammulinksnews.com
Freenome's new CEO is ready to compete in race for tests that can detect cancer earlySan Francisco Business Times - The Business Journals
Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences - Benzinga
Guardant Health (GH): director Tariq Musa sells $5591 in stock By Investing.com - Investing.com South Africa
Guardant Health (GH): director Tariq Musa sells $5591 in stock - Investing.com
Guardant Health Director Sells 142 Shares at $48.2 Per Share on 2025-07-17. - AInvest
Global Liquid Biopsy Market Size Worth USD 25.24 Billion By 2032 | - openPR.com
Lung Cancer Diagnostics Market Expansion Driven by Liquid - openPR.com
(GH) Technical Data - news.stocktradersdaily.com
User - FinancialContent
Evercore ISI Keeps Their Buy Rating on Guardant Health (GH) - The Globe and Mail
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 - BioSpace
Guardant Health stock price target maintained at $60 by Evercore ISI - Investing.com Canada
What makes Guardant Health Inc. stock price move sharplyFree Stock Portfolio Optimization - beatles.ru
Press Release: Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 - 富途牛牛
Quinn Emanuel Sanctioned For Ad Case 'Misrepresentations' - Law360
Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know - MSN
US judge rebukes law firm Quinn Emanuel, awards $3 million sanction in Guardant case - Reuters
East Bay company looks to bring cancer insights to rheumatoid arthritisSan Francisco Business Times - The Business Journals
Precision Medicine Market worth $246.66 billion by 2029 with 11.1% CAGRRIVER COUNTRY - RIVER COUNTRY - NEWS CHANNEL NEBRASKA
Guardant Health Insider Sold Shares Worth $5,087,630, According to a Recent SEC Filing - MarketScreener
The 5 Most Interesting Analyst Questions From Guardant Health’s Q1 Earnings Call - Yahoo Finance
Is GH's Q1 2025 forecast achievable? - AInvest
Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care - MSN
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer - The Lancet
Guardant Health’s Colorectal Cancer Screening Test Earns Another Honor - Medical Product Outsourcing
Precision Medicine: The Future of Healthcare? Companies Like Tempus AI, Guardant Health, and Exact Sciences Are Pioneering the Way - AInvest
Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out - Benzinga
Guardant Health gets Breakthrough Device Designation from FDA for cancer detection test - Mugglehead Magazine
Medical Services Stock Near A Buy Point, It Just Needs A Boost - Investor's Business Daily
Guardant Health Elects Board and Approves Auditor - TipRanks
Guardant Health, Inc. (NASDAQ:GH) Looks Just Right With A 26% Price Jump - simplywall.st
Guardant Health’s Multi-Cancer Detection Test Wins FDA Breakthrough Designation - Medical Product Outsourcing
Australian biotech uncovers broader view of tumour genetics with liquid biopsy - Mugglehead Magazine
Guardant Health director sells shares worth $157,573 By Investing.com - Investing.com UK
Insider Sell: Meghan Joyce Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health director sells shares worth $157,573 - Investing.com
Guardant Health Executives Sell Shares - TradingView
Guardant Health up 4% on Q1 beats, 2025 guidance revenue raise - MSN
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.06%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):